• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性胸膜间皮瘤:最新进展。

Malignant pleural mesothelioma: an update.

机构信息

Instituto International de Pesquisa, A.C. Camargo Cancer Center, São Paulo (SP), Brasil.

Instituto Nacional de Oncogenômica e Inovação Terapêutica, São Paulo (SP), Brasil.

出版信息

J Bras Pneumol. 2021 Dec 13;47(6):e20210129. doi: 10.36416/1806-3756/e20210129. eCollection 2021.

DOI:10.36416/1806-3756/e20210129
PMID:34909922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8836658/
Abstract

Malignant mesotheliomas are rare types of cancers that affect the mesothelial surfaces, usually the pleura and peritoneum. They are associated with asbestos exposure, but due to a latency period of more than 30 years and difficult diagnosis, most cases are not detected until they reach advanced stages. Treatment options for this tumor type are very limited and survival ranges from 12 to 36 months. This review discusses the molecular physiopathology, current diagnosis, and latest therapeutic options for this disease.

摘要

恶性间皮瘤是一种罕见的癌症,影响间皮表面,通常是胸膜和腹膜。它们与石棉暴露有关,但由于潜伏期超过 30 年且诊断困难,大多数病例在达到晚期阶段之前都无法检测到。这种肿瘤类型的治疗选择非常有限,存活时间从 12 到 36 个月不等。本文综述了该疾病的分子病理生理学、当前诊断和最新治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/eca1c94380b2/jbpneu-47-6-e20210129-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/0fc8ec39d07d/jbpneu-47-6-e20210129-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/0eab6b098c59/jbpneu-47-6-e20210129-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/cc2083f94963/jbpneu-47-6-e20210129-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/eca1c94380b2/jbpneu-47-6-e20210129-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/0fc8ec39d07d/jbpneu-47-6-e20210129-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/0eab6b098c59/jbpneu-47-6-e20210129-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/cc2083f94963/jbpneu-47-6-e20210129-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fae9/8836658/eca1c94380b2/jbpneu-47-6-e20210129-g04.jpg

相似文献

1
Malignant pleural mesothelioma: an update.恶性胸膜间皮瘤:最新进展。
J Bras Pneumol. 2021 Dec 13;47(6):e20210129. doi: 10.36416/1806-3756/e20210129. eCollection 2021.
2
NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.NCCN 指南洞察:间皮瘤:胸膜,版本 1.2024。
J Natl Compr Canc Netw. 2024 Mar;22(2):72-81. doi: 10.6004/jnccn.2024.0014.
3
Near Missed Case of Occupational Pleural Malignant Mesothelioma, a Case Report and Latest Therapeutic Options.职业性胸膜恶性间皮瘤错失病例报告及最新治疗选择
Int J Environ Res Public Health. 2022 Nov 10;19(22):14763. doi: 10.3390/ijerph192214763.
4
[Coincident manifestation of mesotheliomas of the tunica vaginalis and pleura. Case report and literature overview].[鞘膜和胸膜间皮瘤的同时表现。病例报告及文献综述]
Urologe A. 2008 Feb;47(2):200-4. doi: 10.1007/s00120-007-1576-2.
5
Diffuse epithelioid malignant mesothelioma of the pleura presenting as a hydropneumothorax and vertebral body invasion.表现为血气胸和椎体侵犯的弥漫性上皮样恶性胸膜间皮瘤。
BMJ Case Rep. 2020 Jan 2;13(1):e231987. doi: 10.1136/bcr-2019-231987.
6
The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review.微小RNA在恶性胸膜间皮瘤诊断与治疗中的作用——简短综述
Microrna. 2012;1(1):40-8. doi: 10.2174/2211536611201010040.
7
[The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma - An Expert Consensus Paper].[石棉相关恶性胸膜间皮瘤的当前治疗——专家共识文件]
Pneumologie. 2021 Oct;75(10):776-794. doi: 10.1055/a-1404-1562. Epub 2021 May 4.
8
Non-asbestos-related malignant pleural mesothelioma.非石棉相关的恶性胸膜间皮瘤
Intern Med. 2014;53(17):1977-9. doi: 10.2169/internalmedicine.53.0900. Epub 2014 Sep 1.
9
Malignant mesothelioma: risk factors and current management.恶性间皮瘤:危险因素与当前治疗方法
Nurs Times. 2004;100(16):40-3.
10
Update on biology and management of mesothelioma.间皮瘤的生物学和治疗进展。
Eur Respir Rev. 2021 Jan 19;30(159). doi: 10.1183/16000617.0226-2020. Print 2021 Mar 31.

引用本文的文献

1
Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives.联合化疗药物、靶向治疗、疫苗和天然生物活性化合物治疗间皮瘤:进展与展望
Oncol Res. 2025 Aug 28;33(9):2181-2204. doi: 10.32604/or.2025.066708. eCollection 2025.
2
A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value.一种有前景的胸膜间皮瘤预后指标:全免疫炎症值。
J Clin Med. 2025 Aug 4;14(15):5467. doi: 10.3390/jcm14155467.
3
The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions.

本文引用的文献

1
Pleural mesothelioma classification update.胸膜间皮瘤分类更新。
Virchows Arch. 2021 Jan;478(1):59-72. doi: 10.1007/s00428-021-03031-7. Epub 2021 Jan 21.
2
Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial.根治性半胸放疗与姑息性放疗治疗非转移性恶性胸膜间皮瘤的随机 3 期临床试验结果。
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1368-1376. doi: 10.1016/j.ijrobp.2020.11.057. Epub 2020 Nov 28.
3
Pathology of Malignant Pleural Mesothelioma.
化疗在胸膜恶性肿瘤治疗中的角色演变:当前证据与未来方向
Cancers (Basel). 2025 Jun 25;17(13):2143. doi: 10.3390/cancers17132143.
4
Mortality rate for mesothelioma as a basic cause in the period 2017-2022 in Chile.2017 - 2022年期间,智利以间皮瘤为主要病因的死亡率。
Ecancermedicalscience. 2025 Jun 18;19:1927. doi: 10.3332/ecancer.2025.1927. eCollection 2025.
5
Computer-Aided Discovery of Natural Compounds Targeting the ADAR2 dsRBD2-RNA Interface and Computational Modeling of Full-Length ADAR2 Protein Structure.靶向ADAR2双链RNA结合结构域2-RNA界面的天然化合物的计算机辅助发现及全长ADAR2蛋白质结构的计算建模
Int J Mol Sci. 2025 Apr 25;26(9):4075. doi: 10.3390/ijms26094075.
6
Prognostic Value of Chest CT Volumetric Analysis in Patients with Malignant Pleural Mesothelioma.胸部CT容积分析在恶性胸膜间皮瘤患者中的预后价值
J Clin Med. 2025 Feb 25;14(5):1547. doi: 10.3390/jcm14051547.
7
Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma.PD-L1、BAP-1和整合素连接激酶在胸膜间皮瘤中的预后价值
J Clin Med. 2024 Dec 2;13(23):7322. doi: 10.3390/jcm13237322.
8
Diffuse Pleural Mesothelioma: A Challenge in Early Diagnosis.弥漫性胸膜间皮瘤:早期诊断的挑战
Cureus. 2024 Dec 2;16(12):e74998. doi: 10.7759/cureus.74998. eCollection 2024 Dec.
9
Capsaicin Exerts Antitumor Activity in Mesothelioma Cells.辣椒素对间皮瘤细胞具有抗肿瘤活性。
Nutrients. 2024 Nov 1;16(21):3758. doi: 10.3390/nu16213758.
10
Malignant Pleural Mesothelioma: A Comprehensive Review.恶性胸膜间皮瘤:综述
J Clin Med. 2024 Sep 30;13(19):5837. doi: 10.3390/jcm13195837.
恶性胸膜间皮瘤的病理学
Thorac Surg Clin. 2020 Nov;30(4):367-382. doi: 10.1016/j.thorsurg.2020.08.007.
4
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.一项比较派姆单抗与单药化疗治疗晚期预处理恶性胸膜间皮瘤的多中心随机 III 期试验:欧洲胸部肿瘤平台(ETOP 9-15)PROMISE-meso 试验。
Ann Oncol. 2020 Dec;31(12):1734-1745. doi: 10.1016/j.annonc.2020.09.009. Epub 2020 Sep 22.
5
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.度伐利尤单抗联合一线化疗用于未经治疗的恶性胸膜间皮瘤(DREAM):一项多中心、单臂、Ⅱ期、有安全爬坡阶段的研究
Lancet Oncol. 2020 Sep;21(9):1213-1223. doi: 10.1016/S1470-2045(20)30462-9.
6
The Separation of Benign and Malignant Mesothelial Proliferations: New Markers and How to Use Them.良性和恶性间皮增生的鉴别:新的标志物及其应用。
Am J Surg Pathol. 2020 Nov;44(11):e100-e112. doi: 10.1097/PAS.0000000000001565.
7
Adenomatoid Tumor: A Review of Pathology With Focus on Unusual Presentations and Sites, Histogenesis, Differential Diagnosis, and Molecular and Clinical Aspects With a Historic Overview of Its Description.腺瘤样肿瘤:病理复习,重点关注不常见的表现和部位、组织发生、鉴别诊断以及分子和临床方面,并对其描述进行历史回顾。
Adv Anat Pathol. 2020 Nov;27(6):394-407. doi: 10.1097/PAP.0000000000000278.
8
Mesothelioma in the age of "Omics": Before and after The Cancer Genome Atlas.间皮瘤的“组学”时代:从癌症基因组图谱之前到之后。
J Thorac Cardiovasc Surg. 2020 Oct;160(4):1078-1083.e2. doi: 10.1016/j.jtcvs.2020.02.141. Epub 2020 May 29.
9
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.恶性胸膜间皮瘤的遗传改变:与肿瘤异质性和总生存的关系。
Mol Oncol. 2020 Jun;14(6):1207-1223. doi: 10.1002/1878-0261.12651. Epub 2020 Mar 10.
10
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.EURACAN/IASLC 提出更新胸膜间皮瘤组织学分类的建议:采用更具多学科性的方法。
J Thorac Oncol. 2020 Jan;15(1):29-49. doi: 10.1016/j.jtho.2019.08.2506. Epub 2019 Sep 20.